Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Zenas BioPharma, Inc. (ZBIO : NSDQ)

• Company Description    Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass. Number of Employees: 130

• Price / Volume Information    Yesterday's Closing Price: $20.23 Daily Weekly Monthly 20 Day Moving Average: 225,086 shares Shares Outstanding: 42.11 (millions) Market Capitalization: $851.89 (millions) Beta: 52 Week High: $26.25 52 Week Low: $5.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.70% 18.58% 12 Week 117.29% 97.38% Year To Date 147.01% 119.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 852 Winter Street Suite 250 - Waltham,MA 02451 USA ph: 857-271-2954 fax: - zenas@argotpartners.com http://www.zenasbio.com

• General Corporate Information    Officers Leon O. Moulder - Chief Executive Officer and Director Jennifer Fox - ChiefFinancial Officer;Chief Business Officer Patricia Allen - Director James Boylan - Director Patrick Enright - Director Peer Information Zenas BioPharma, Inc. (CORR.) Zenas BioPharma, Inc. (RSPI) Zenas BioPharma, Inc. (CGXP) Zenas BioPharma, Inc. (BGEN) Zenas BioPharma, Inc. (GTBP) Zenas BioPharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98937L105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 42.11 Most Recent Split Date: (:1) Beta: Market Capitalization: $851.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.87 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.53 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -56.25% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 100.00% ROE 06/30/25 - -59.21 03/31/25 - -68.09 12/31/24 - -93.46 ROA 06/30/25 - -50.56 03/31/25 - -58.80 12/31/24 - -81.19 Current Ratio 06/30/25 - 5.23 03/31/25 - 6.47 12/31/24 - 6.21 Quick Ratio 06/30/25 - 5.23 03/31/25 - 6.47 12/31/24 - 6.21 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -1,178.42 03/31/25 - -1,083.58 12/31/24 - -3,131.18 Book Value 06/30/25 - 5.73 03/31/25 - 6.80 12/31/24 - 7.48 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©